

Bo Fu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11812163/publications.pdf>

Version: 2024-02-01

8
papers

694
citations

1307594
7
h-index

1720034
7
g-index

8
all docs

8
docs citations

8
times ranked

1302
citing authors

#	ARTICLE	IF	CITATIONS
1	Glecaprevir/Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. <i>New England Journal of Medicine</i> , 2018, 378, 354-369.	27.0	361
2	Mild cognitive impairment. <i>Neurology</i> , 2013, 80, 2112-2120.	1.1	120
3	Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. <i>Hepatology</i> , 2018, 67, 505-513.	7.3	94
4	Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	38
5	Vascular Risk Factors and Cognitive Decline in a Population Sample. <i>Alzheimer Disease and Associated Disorders</i> , 2014, 28, 9-15.	1.3	35
6	Old Worries and New Anxieties: Behavioral Symptoms and Mild Cognitive Impairment in a Population Study. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 274-284.	1.2	32
7	High antiviral activity of NS5A inhibitor ABT530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection. <i>Liver International</i> , 2016, 36, 1125-1132.	3.9	14
8	Hepatitis C in Liver Allograft Recipients: Utility of One-Year Post-Transplantation Biopsy as an Indicator of Antiviral Therapy. <i>Gastroenterology Research</i> , 2015, 8, 281-290.	1.3	0